Cell Biology Engineering Therapies 
Chemical Biology and Drug Design
JULY 26, 2023
Exosome engineering can be conducted through surface and content modification of biological exosomes. In preisolation method, parental cells are stimulated to express some special genes like lncRNAs, miRNAs, and receptors to have the capacity to bind to the target cells and deliver their content.
Drug Target Review
NOVEMBER 17, 2023
They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells). NK cells can be readily extracted from umbilical cord blood or peripheral blood of adult donors.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
OCTOBER 2, 2024
Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. However, cell-based therapies are intended to leverage those healthy cells via transplant to regenerate damaged tissue.
Drug Target Review
OCTOBER 16, 2023
Two-dimensional cell models were the cornerstone of cellular assays in early drug discovery for years, yet the system lacks the genetic and epigenetic background of the patient and the cell-to-cell spatial architecture and cellular signalling between cells of different types within the tissue architecture.
Broad Institute
OCTOBER 11, 2023
By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. The team found that deleting the gene Ptpn2 made tumors sensitive to PD-1 therapy, and they published their findings in Nature in 2017.
Drug Target Review
JUNE 7, 2024
How does Immunocore’s TCR technology differentiate itself from other approaches to targeted cancer therapy? Can you explain the mechanism of action by which ImmTAC molecules selectively target and kill cancer cells?
Drug Target Review
JUNE 5, 2023
ZW191 is an antibody-drug conjugate (ADC) that is engineered to target folate receptor-⍺ (FR⍺), a protein that has limited expression in normal tissues but is often elevated on a variety of tumours including epithelial ovarian, endometrial, triple negative breast and lung adenocarcinoma.
Expert insights. Personalized for you.
100 
Let's personalize your content